Skip to main content
. Author manuscript; available in PMC: 2022 Jul 7.
Published in final edited form as: J Thorac Oncol. 2021 Apr 8;16(7):1149–1165. doi: 10.1016/j.jtho.2021.03.013

Figure 5. Efficacy of PI3K, MTOR and MEK inhibitors on growth of NRG1-rearranged cell lines.

Figure 5.

Cells were treated for 96 h with the indicated concentrations of inhibitors and then growth determined using alamarBlue proliferation dye. Results represent the mean ± SD of 2–4 experiments in which each condition was assayed in triplicate determination. The MTOR inhibitors rapamycin (A) and everolimus (B) suppressed growth of LUAD-0061AS3cl at low nanomolar doses, while much higher doses were required to inhibit MDA-MB-175-VII cell line. (C) LUAD-0061AS3 and MDA-MB-175-VII cells were treated with rapamycin for 48 h and then caspase 3/7 activity determined. Results represent the mean ± SD of two independent experiments in which each condition was assayed in triplicate determination. *Treatment compared to untreated controls for LUAD-0061AS3, ANOVA. Values were not significantly different for MDA-MB-175-VII. D-F. MEK inhibitors demonstrated higher activity in MDA-MB-175-VII cells (D), while no difference in sensitivity to the PI3K inhibitors alpelisib and pictilisib between cell lines was observed (E, F). G. Comparison of MAPK pathway activation in the cell lines. Immunoblots for p-ERK and p-BRAF shown in Figure 3D was quantitated by densitometry.